Friday, 20 November 2026NewsWorldBusinessTech
Latest

Colorectal Cancer Rates Rise After 20-Year Decline, Study Finds

Colorectal cancer incidence rates in the United States reversed more than 20 years of decline when cases rose to 38.3 per 100,000 people in 2023, according to a study published in NEJM Evidence.

Colorectal Cancer Rates Rise Again

Recorded at 55.2 per 100,000 in 2000, the age-adjusted incidence rate dropped to 36.7 per 100,000 by 2022. It reached 38.3 per 100,000 in 2023. Researchers analyzing data from the National Cancer Institute found that the rate dropped from 55.2 cases per 100,000 in 2000 down to 36.7 in 2022 before climbing upward the following year.

The rate was 55.2 per 100,000 (95% CI, 54.8 to 55.6) in 2000. It shifted to 36.7 per 100,000 (95% CI, 36.4 to 37.0) by 2022. It reached 38.3 per 100,000 (95% CI, 38.0 to 38.6) in 2023.

Financial support for the research, entitled “Colorectal Cancer among U.S. Adults, 2000–2023,” was provided by the National Institutes of Health. Funding also came from the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Ablon Scholars Program. Analyses were conducted by using SEER*Stat version 9.0.43.0 and Joinpoint Regression Software version 6.0.1.

Statistical models further demonstrated that between 2000 and 2019, the age-adjusted incidence rate experienced a year-over-year decline. Annual percent changes spanned from −3.74 (95% CI, −4.71 to −3.02) to −0.86 (95% CI, −1.24 to −0.55). Conversely, between 2021 and 2023, the age-adjusted incidence rate rose annually at a rate of 2.76% (95% CI, 0.78 to 3.86).

“This is the first time that we have seen an increase in the overall rate since in more than 20 years,” said Caitlin Murphy, professor of pediatrics and public health sciences at the University of Chicago.

Colorectal cancer remains the second-leading cause of cancer-related deaths overall in the United States. It is the top killer of adults under 50. The rising incidence extends beyond the adults under 50 who have driven recent public health warnings. The new findings show case rates climbing across nearly all age groups up to age 65 to 69.

Data compiled by the American Cancer Society covering 2013 to 2022 indicate that among adults aged 20 to 49 years, colorectal cancer incidence rates climbed at an annual rate of 3%.

Colorectal Cancer Rates Rise After 20-Year Decline, Study Finds
Photo: Docwirenews

Screening Changes and Birth Cohorts

The steepest surge in case frequencies was observed among people aged 45 to 49. They experienced a yearly jump of 12.76% between 2019 and 2023. Investigators said that this upward trend is likely propelled by a greater volume of screenings taking place after national guidelines adjusted the recommended starting age from 50 down to 45.

“That means that screening is doing as we intend it to do—it’s catching cancer earlier,” Murphy said.

Screening expansions do not explain the rise. Rates are climbing among people aged 65 to 69 and holding steady among those 70 to 74. Approximately 80% of people in those older brackets are up to date on screening.

Researchers point to a birth cohort effect as a contributing factor. People born in the 1960s and later face an increased risk of developing the disease as they reach middle age and older adulthood.

“As people born around the same time move through time and age together, we’re going to see more colorectal cancers being diagnosed,” Murphy explained.

To investigate underlying causes, scientists are examining environmental chemical exposures. They are also planning laboratory tests using colon organoids.

Investigators evaluated whether COVID-19 pandemic disruptions influenced the data. They found that incidence increases persisted even when excluding figures from 2020 and 2021.

Data from 2020 were excluded from the joinpoint analysis due to pandemic-related disruptions. Investigators explained this was recommended by the National Cancer Institute.

The University of Chicago, a private research university in Hyde Park, Illinois, was re-established in 1890 with funding from John D. Rockefeller and land from Marshall Field after an earlier Baptist institution closed in 1886. The university operates Fermi National Accelerator Laboratory and Argonne National Laboratory, and its faculty and alumni have included 102 Nobel laureates as of 2026.

“These results motivate us to understand reasons for this rise, so risk factors can be identified and possibly reduced,” said Sonia Kupfer, director of the Gastrointestinal Cancer Risk and Prevention Clinic at UChicago Medicine.